Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab and MVA HIV-B Vaccine in HIV-1
NCT04120415Phase 2Completed
- Sponsor
- ANRS
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Vaccines & Immunotherapeutics, Viral Vectors
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of vedolizumab and MVA-B in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by ANRS. Primary endpoint: Area under the HIV RNA curve. Started Jun 2022; status: completed.
02
Drugs
vedolizumabMVA-B
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04120415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120415.